A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body. This study was conducted by ...
Sep 6, 2021
0
265
The RB1 tumor suppressor gene protein antagonizes uncontrolled growth of cancer by suppressing cell cycle progression but its function is repressed in most cancers. CDK4/6 represses this function by phosphorylating RB1. In ...
Sep 2, 2021
0
2
More than 43,000 American women will die from breast cancer this year. Most of those deaths will occur after the cancer has spread to other organs, a process called metastasis. This involves at least five major steps. Two ...
Aug 18, 2021
0
296
Immunotherapy has become an important tool in the treatment of lung cancer, especially checkpoint inhibitors that block certain immune checkpoints to allow immune cells to recognize and kill cancer cells. Several checkpoint ...
Aug 12, 2021
0
106
Lung cancer is the leading cause of cancer-related death. Current treatments employ immunotherapy, often in combination with chemotherapy, but benefits to patients remain slight. In a pre-clinical study, EPFL researchers ...
Aug 11, 2021
0
100
When a doctor gives a patient antibiotics for a bacterial infection, they usually require them to finish the entire treatment, even when symptoms go away. This is to ensure the drugs kill off any remaining bacteria. Cold ...
Jul 13, 2021
0
8
Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them.
Jun 18, 2021
0
16
An investigational antibody in clinical trials for lung cancer appears to disrupt a mechanism that tumor cells exploit to avoid being destroyed by the body's innate immune system, researchers at Duke Health report.
Jun 17, 2021
0
19
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai ...
Jun 16, 2021
0
7
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was ...
Jun 10, 2021
0
1
